Profound Med Corp Stock Price, News & Analysis

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) will participate in two upcoming investor conferences in March. The 42nd Annual Cowen Health Care Conference is scheduled for March 7, 2022, at 10:30 a.m. ET, and the Raymond James 43rd Annual Institutional Investors Conference will follow on March 9, 2022, at 9:50 a.m. ET. Both presentations will be accessible via live broadcast and archived on Profound's website. Profound specializes in customizable, incision-free therapies for the ablation of diseased tissue, including TULSA-PRO® and Sonalleve® technologies.

Profound Medical Corp. (NASDAQ:PROF) announced the first agreement for its TULSA-PRO® system compatible with GE Healthcare’s 3T MRI scanners, signed with Brigham and Women's Hospital. This partnership aims to enhance the treatment of prostate cancer, which is increasingly prevalent worldwide. CEO Arun Menawat highlighted that this compatibility could boost market access by 30-40%. TULSA-PRO® is designed for incision-free ablation of diseased prostate tissue while preserving healthy areas, with CE, Health Canada, and FDA clearances.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) will announce its fourth quarter and full-year 2021 financial results on March 3, 2022, after market close. The management will host a conference call at 4:30 p.m. ET to review these results and discuss business developments. Profound specializes in customizable, incision-free therapies for tissue ablation, notably the TULSA-PRO® and Sonalleve® technologies. These devices address conditions like prostate cancer and uterine fibroids and have received necessary regulatory approvals from CE, Health Canada, and the U.S. FDA.

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) announced its management's participation in the BTIG MedTech Conference scheduled from February 15-17, 2022. The event will feature one-on-one investor meetings but will not include a webcast. Profound specializes in incision-free medical therapies, notably the TULSA-PRO® system for prostate cancer treatment and the Sonalleve® platform for uterine fibroids and palliative pain. Both technologies are CE marked and FDA approved, positioning Profound as a leader in innovative medical solutions.

Profound Medical Corp. (NASDAQ:PROF) has initiated the Level 1 CAPTAIN trial, which compares the TULSA procedure to radical prostatectomy (RP) in men with localized prostate cancer. The trial includes 201 patients, with 134 receiving TULSA and 67 undergoing RP. It aims to demonstrate that TULSA maintains efficacy while improving quality of life outcomes, focusing on preserving erectile function and urinary continence at one year. Successful results could enhance reimbursement strategies and expand awareness of TULSA-PRO, a leading technology in prostate cancer treatment.

Profound Medical Corp. has appointed Kenneth Knudson as Chief Commercial Officer to lead global sales, marketing, and reimbursement initiatives. With over 25 years of experience in the medical device sector, Knudson previously served as CEO of Perineologic and held executive positions at Boston Scientific. His leadership is expected to enhance the commercialization of Profound's technologies, including TULSA-PRO® and Sonalleve®. TULSA-PRO® provides incision-free prostate ablation, while Sonalleve® treats uterine fibroids and pain from bone metastases. Both technologies have received regulatory approvals in various markets.

Profound Medical Corp. (NASDAQ: PROF) reported Q3 2021 financial results, revealing revenue of approximately $2.5 million, a 13% increase from $2.2 million year-over-year. The revenue comprised $1.4 million from capital equipment sales and $1.1 million from recurring sources. Operating expenses rose to $8.6 million, a 30% increase. The net loss narrowed slightly to $6.0 million, or $0.29 per share, compared to $6.1 million in Q3 2020. As of September 30, 2021, cash reserves were approximately $72.2 million.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced its participation in two investor conferences this November. On November 18, it will engage in one-on-one meetings during the Canaccord Genuity Virtual MedTech Forum. Additionally, Profound will host a pre-recorded fireside chat at the Jefferies London Healthcare Conference, available on-demand from 3:00 a.m. ET on the same day. Profound specializes in customizable, incision-free therapies for tissue ablation, notably its TULSA-PRO^® and Sonalleve^® technologies, which have received various regulatory approvals.

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) will announce its third quarter 2021 financial results on November 4, 2021, after market close. A conference call will be held at 4:30 p.m. ET the same day to discuss the results and business developments. Profound specializes in customizable, incision-free therapies for diseased tissue, including the TULSA-PRO® system for prostate ablation and Sonalleve® for uterine fibroids. Both technologies have received necessary regulatory approvals, enhancing their market potential.